Video

Potential Molecular Markers in Liver Cancer

Anuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.

Anuradha S. Budhu, PhD, senior associate scientist, Laboratory of Human Carcinogenesis, program manager, Liver Cancer Program, Center for Cancer Research, National Cancer Institute, discusses using molecular features as predictive markers in liver cancer.

Genes are an important molecular feature that can shed light on individual biology, says Budhu. As such, investigators compare normally expressed genes with dysregulated or overexpressed genes to gain insight on cancer biology.

Other potential markers include microRNAs and downstream affecters of gene signaling such as metabolites and proteins, says Budhu.

By measuring the abundance of these features, investigators are aiming to understand tumor biology. These markers may help to identify liver cancer in patients, predict the aggressiveness of the disease, and determine which patients will benefit the most from treatment.

Related Videos
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD